Treatment of Parkinsonism
Over the last decade the treatment of Parkinsonism has under gone major developments. Advances deriving from a logically structured series of laboratory experiments have been transferred to the clinic to generate substantial therapeutic achievements.
KeywordsDopamine Dementia Serotonin Neurol Alkaloid
Unable to display preview. Download preview PDF.
- Cools, A.R. and Van Rossum, J.M. (1975). Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharma- cologia (Berl). 45 ,243–254.CrossRefGoogle Scholar
- Jaton, A.L., Loew, D.M. and Vigouret, J.M. (1975). CF 25–397 (9,10 didehydro-6-methyl-8ß-[2-pyridylthiomethyl] ergoline), anew central dopamine receptor agonist. Proc B.P.S. 56 ,371.Google Scholar
- Kartzinel, R., Perlow, M.J., Carter, A.C., Chase, T.N. and Calne, D.B. (1976). Metabolic studies with bromocriptine in patients with idiopathic Parkinsonism and Huntington’s Chorea. Trans Am Neurol Assoc. In press.Google Scholar
- Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1973). Metabolism of levodopa in the human brain. In Advances in Neurology, Vol. 3, (Calne, D.B., Ed.) pp. 173–188. Raven Press, New York.Google Scholar
- McLennan, H. and York, D.H. (1967). The action of dopamine on neurons of the caudate nucleus. J. Physiol. (Lond). 189 ,393–402.Google Scholar
- Silbergeld, E.K., Adler, H., Kennedy, S. and Calne, D.B. (1976).Roles of presynaptic dopamine function and hepatic drug metabolism in effects of three dopamine agonists: bromocriptine, lergotrile and CF25-397. In press.Google Scholar
- Silbergeld, E.K. and Pfeiffer, R.F. (1976). Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile. In press.Google Scholar
- Teychenne, P.F., Jones, A. and Calne, D.B. (1976). Changes in liver function induced by lergotrile. In preparation.Google Scholar
- Teychenne, P.F., Pfeiffer, R.F. and Calne, D.B. (1976). Actions of CF25–397 in parkinsonism. In preparation.Google Scholar
- Yahr, M.D. (ed.) (1973). In Advances in Neurology, Vol. 2-Treatment of Parkinson’s Disease-the Use of Dopa Deoarboxylase Inhibitors. pp. 303. Raven Press, New York.Google Scholar
- Yahr, M.D. (1975). Levodopa. Ann Intern Med. 83 ,667–682.Google Scholar